Cite
Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
MLA
Clare Proudfoot, et al. “Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.” Journal of Managed Carespecialty Pharmacy, vol. 25, no. 11, Oct. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c7a34664573f06b19a66399c54da8f0a&authtype=sso&custid=ns315887.
APA
Clare Proudfoot, Chieh I. Chen, Zsofia Kiss, Noemi Muszbek, Peter Gal, Kaleb Michaud, Marie Fournier, & Andreas Kuznik. (2019). Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Journal of Managed Carespecialty Pharmacy, 25(11).
Chicago
Clare Proudfoot, Chieh I. Chen, Zsofia Kiss, Noemi Muszbek, Peter Gal, Kaleb Michaud, Marie Fournier, and Andreas Kuznik. 2019. “Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.” Journal of Managed Carespecialty Pharmacy 25 (11). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c7a34664573f06b19a66399c54da8f0a&authtype=sso&custid=ns315887.